Skip to main content

Table 2 Information used to evaluate the proportion of patients achieving a response according to common criteria used in RA studiesa

From: Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors

Measure Number of biologics used Number of patients Estimated response rate, % Specific biologics used to derive response rate Treatment duration range, months Mean age range, yr Mean RA duration range, yr Reference sources
ACR20 1 5,762 70.0 ADA 6 to 12 53 to 56 11 to 16 [30, 36, 51]
  2 1,911 52.7 ADA, ETN, GLM, IFX, TCZ, TNF2 3 to 12 45 to 57 9 to 17 [14, 15, 17, 30, 32, 34, 36, 37, 51–53]
  2+ 772 53.3 ABA, RTX 6 to 12 52 to 53 12 [39, 41, 42]
  3 339 40.6 ADA, GLM, TCZ, TNF3 3 to 6 51 to 58 11 to 15 [17, 32, 36, 52]
  4 66 31.9 GLM, TCZ 4 to 6 51 to 54 11 to 13 [32, 52]
ACR50 1 5,736 41.1 ADA 3 to 12 54 to 56 11 to 16 [36, 51]
  2 1,699 30.1 ETN, TCZ, TNF2, ADA, IFX 3 to 12 45 to 57 9 to 17 [14, 15, 17, 32, 34, 36, 37, 47, 51]
  2+ 1,078 23.5 GLM, ABA, RTX 4 to 12 52 to 55 9 to 12 [39, 41, 42, 52]
  3 268 24.4 TCZ, TNF3, ADA 3 to 6 51 to 58 11 to 15 [17, 32, 36]
  4 44 20.5 TCZ 6 51 to 54 11 to 13 [32]
ACR70 1 5,736 19.1 ADA 3 to 12 54 to 56 11 to 16 [36, 51]
  2 1,686 12.0 ADA, ETN, TCZ, TNF2 3 to 12 49 to 57 8 to 17 [5, 17, 32, 34, 36, 37, 47, 51, 53]
  2+ 1,078 11.9 ABA, GLM, RTX 4 to 12 52 to 55 9 to 12 [39, 41, 42, 52]
  3 268 12.7 ADA, TCZ, TNF3 3 to 6 51 to 58 11 to 15 [17, 32, 36]
  4 44 4.5 TCZ 6 51 to 54 11 to 13 [32]
DAS28 <2.6 1 5,711 21.0 ADA 3 54 11 [36]
  2 1,604 14.9 ABA, ADA, TNF2 3 to 6 53 to 56 12 to 14 [17, 29, 36]
  2+ 331 19.2 TCZ 6 51 to 54 11 to 13 [36]
  3 496 10.2 ABA, ADA, TNF3 3 to 6 52 to 58 12 to 15 [17, 29, 36]
  4 200 6.5 ABA 6 56 - [29]
DAS28 <3.2 2 1,219 22.7 ABA,TNF2 TNTNF2 3 to 6 55 to 56 8 to 14 [17, 29, 40]
  2+ 331 33.7 TCZ 6 51 to 54 11 to 13 [32]
  3 376 21.6 ABA TNF3 3 to 6 56 to 58 15 [17, 29]
  4 200 15.0 ABA 6 56 - [29]
EULAR moderate 1 6,494 48.0 ADA, TNF 3 to 8 54 to 57 8 to 11 [33, 36, 45]
  2 1,854 44.4 ADA, ETN, TNF2 3 to 12 53 to 61 8 to 13 [35–38, 43, 45]
  2+ 324 49.7 TNF, RTX 6 to 9 52 12 [33, 39]
  3 120 51.0 ADA 3 52 12 [36]
EULAR good 1 6,494 34.0 ADA, TNF 3 to 8 54 to 57 8 to 11 [33, 36, 45]
  2 2,232 19.4 ADA, ETN, TNF2 3 to 12 53 to 61 8 to 14 [17, 36–38, 43–45, 53]
  2+ 324 15.3 TNF2+, RTX 6 to 9 52 12 [33, 45]
  3 156 10.5 ADA, TNF3 3 52 to 58 12 to 15 [17, 36]
  1. aRA, rheumatoid arthritis; ACR, American College of Rheumatology; DAS28, Disease Activity Score 28 joint count; EULAR, European League Against Rheumatism. ABA, abatacept, ADA, adamlimumab, ANA, anakinra, ETN, etanercept, GLM, golimumab, IFX, infliximab, RTX, rituximab, TNFi, ith TNF-α inhibitor, TCZ, tocilizumab. ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories adhere to the same criteria, but for 50% and 70% improvement, respectively.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us